SEARCH:   Advanced

Blood, 1 July 2007, Vol. 110, No. 1, pp. 375-379. Prepublished online as a Blood First Edition Paper on March 15, 2007; DOI 10.1182/blood-2006-12-062125. This Article Abstract Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-12-062125v1 110/1/375    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Theocharides, A. Articles by Skoda, R. C. Search for Related Content PubMed PubMed Citation Articles by Theocharides, A. Articles by Skoda, R. C. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief Report Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Alexandre Theocharides1,2, Marjorie Boissinot3, François Girodon4, Richard Garand5, Soon-Siong Teo1, Eric Lippert6, Pascaline Talmant5, Andre Tichelli7, Sylvie Hermouet3,5, and Radek C. Skoda1 1 Department of Research, Experimental Hematology, University Hospital Basel, Switzerland; 2 Division of Clinical Hematology, University Hospital Basel, Switzerland; 3 Institut National de la Santé et de la Recherche Médicale Unité 601, Institut de Biologie, Nantes, France; 4 Laboratoire d'Hématologie, Centre Hospitalier Universitaire (CHU) de Dijon, France; 5 Laboratoire d'Hématologie, CHU de Nantes, France; 6 Laboratoire d'Hématologie, CHU de Bordeaux, France; 7 Division of Diagnostic Hematology, University Hospital Basel, Switzerland    Abstract Top Abstract Introduction Materials and methods Results and discussion Authorship References   To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to acute myeloid leukemia (AML). At MPD diagnosis, JAK2-V617F was detectable in 17 of 27 patients. Surprisingly, only 5 of 17 patients developed JAK2-V617F–positive AML, whereas 9 of 17 patients transformed to JAK2-V617F–negative AML. Microsatellite analysis in a female patient showed that mitotic recombination was not responsible for the transition from JAK2-V617F–positive MPD to JAK2-V617F–negative AML, and clonality determined by the MPP1 polymorphism demonstrated that the granulocytes and leukemic blasts inactivated the same parental X chromosome. In a second patient positive for JAK2-V617F at transformation, but with JAK2-V617F–negative leukemic blasts, we found del(11q) in all cells examined, suggesting a common clonal origin of MPD and AML. We conclude that JAK2-V617F–positive MPD frequently yields JAK2-V617F–negative AML, and transformation of a common JAK2-V617F–negative ancestor represents a possible mechanism.    Introduction Top Abstract Introduction Materials and methods Results and discussion Authorship References   Myeloproliferative disorders (MPDs) are a heterogeneous group of diseases characterized by increased hematopoiesis leading to elevated numbers of nonlymphoid cells and/or platelets in the peripheral blood. An acquired somatic mutation in the JAK2 gene resulting in a valine-to-phenylalanine substitution at position 617 (JAK2-V617F) is frequently found in patients with MPDs.1–4 Using a sensitive allele-specific polymerase chain reaction (AS-PCR) assay, the JAK2-V617F mutation is detectable in more than 90% of patients with polycythemia vera (PV), more than 50% of essential thrombocythemia (ET), and more than 50% of idiopathic myelofibrosis (IMF).2,5,6 Transformation to acute myeloid leukemia (AML) is a known complication of MPDs.7–9 The frequency of JAK2-V617F in patients with de novo AML was around 1%.10–15 In contrast, the JAK2-V617F mutation in AML secondary to MPD was in the range of 50%.12,14,16 The question of whether the presence of the JAK2-V617F mutation favors leukemic transformation is currently unanswered. Because of the small number of patients with secondary AML, prospective studies are difficult to perform and the data are at present inconclusive.17 Here, we compared the JAK2-V617F status before and at leukemic transformation in 27 MPD patients and performed molecular studies on purified cell populations    Materials and methods Top Abstract Introduction Materials and methods Results and discussion Authorship References   Patients and samples We performed a retrospective study on 27 patients with AML secondary to MPD (8 PV, 12 ET, 7 IMF) from whom samples at MPD and AML diagnosis were available. Informed consent from all patients alive was obtained in accordance with the Declaration of Helsinki. The study was conducted according to the guidelines of the local ethics committees at centers in France (Nantes, Dijon, Bordeaux) and Switzerland (Basel). The diagnosis of MPD was made according to the criteria of the World Health Organization (patients from Basel) or of the Polycythemia Vera Study Group (Nantes, Dijon, Bordeaux).18–20 Cell separations, RNA and DNA isolation Bone marrow or peripheral blood smears were scraped and DNA was isolated using the QIAmp DNA Blood Mini kit (Qiagen, Hilden, Germany). Leukemic blasts were isolated by fluorescence-activated cell sorting (FACS) using side scatter and anti-CD34 antibodies or by laser capture microdissection of bone marrow films stained with May-Grünwald/Giemsa. Cells of the granulocytic lineage and T-cells were sorted by FACS using anti-CD15 and anti-CD3 antibodies, respectively. Purity was greater than 95%. Preparations of DNA and RNA and cDNA syntheses were performed as described.6,21,22 Molecular analyses The methods for detecting loss of heterozygosity on chromosome 9p (9pLOH) and for determining the copy number of chromosome 9p were described earlier.4 A quantitative PCR assay for JAK2-V617F was performed with 2 different methods,6,22 and analysis of clonality by X chromosome inactivation in female patients heterozygous for a single nucleotide polymorphism in the MPP1 gene was assessed as described.22 Statistical analysis To compare continuous variables among the groups we used the Mann-Whitney U test.    Results and discussion Top Abstract Introduction Materials and methods Results and discussion Authorship References   We determined the JAK2-V617F mutation status by AS-PCR in 27 MPD patients (8 PV, 12 ET, and 7 IMF) from whom we obtained paired DNA samples at MPD diagnosis and leukemic transformation. At MPD diagnosis, the JAK2-V617F mutation was present in 17 of 27 patients (63%) (Table 1). Surprisingly, in 7 of these 17 patients, the JAK2 mutation was undetectable in unfractionated peripheral blood or bone marrow samples at transformation to AML. Our AS-PCR assays have a detection limit of less than 1%T.6,22 In 2 additional patients, we found that leukemic blast cells purified by FACS (patient DI-35) or laser capture microdissection (patient NA-48) were negative for JAK2-V617F, although the JAK2 mutation was detectable in unfractionated AML samples (Table 1). Thus, 9 of 17 patients (53%) with JAK2-V617F–positive MPD displayed JAK2-V617F–negative leukemic blasts at diagnosis of AML. Purified granulocytes or CD15-positive myeloid cells obtained in 6 of these 9 patients were also negative for the JAK2 mutation, suggesting that the AML clone exerted a suppressive effect on the JAK2-V617F–positive MPD clone (Table 1). In 5 patients (29%), we found JAK2-V617F both at MPD diagnosis and in leukemic blasts at transformation. In these 5 patients, the allelic ratio of JAK2-V617F in blasts was more than 50%T, suggesting that at least a proportion of blasts were homozygous for JAK2-V617F. In the remaining 3 of 17 patients (18%) with JAK2-V617F–positive MPD, the mutational status of the AML blasts could not be determined with certainty because of a lack of purified cells. View this table: [in this window] [in a new window]   Table 1. Summary of patient characteristics and molecular analyses in AML secondary to MPD   Patients positive for JAK2-V617F at MPD diagnosis who transformed to JAK2-V617F–negative AML had a markedly shorter interval between diagnosis of MPD and leukemic transformation than those who transformed to JAK2-V617F–positive AML (3 ± 2 versus 10 ± 7 years; n = 14; P = .013) (Table S1, available on the Blood website; see the Supplemental Materials link at the top of the online article). Information on treatment during the MPD phase was available in 25 of 27 patients (93%). Two patients transformed to AML without cytoreductive treatment, whereas the remaining patients received hydroxyurea (15 patients), pipobroman (6 patients), or other cytoreductive drugs (Table 1). To address the question whether the MPD and AML clones in these patients arose de novo from different progenitor or stem cells, or represent subclones derived from a common ancestor, we performed molecular analyses in 2 cases. In one female patient with PV (NA-02), we compared clonality by 9pLOH and X chromosomal inactivation pattern (XCIP) in purified cell populations at both stages of the disease (Figure 1). At diagnosis of MPD, this patient had 94%T and displayed 9pLOH (Figure 1A). Deletion of chromosome 9p was excluded by determining the copy number using quantitative PCR (Figure S1). A phase resembling neutrophilic leukemia was observed in this patient 3 months before transformation to AML (white blood cells [WBCs], 159 x 109/L, with 75% neutrophils, 6% metamyelocytes, and 14% myelocytes, but no blasts). At this stage, the neutrophils were already negative for JAK2-V617F (not shown). At transformation to AML, the purified granulocytes and leukemic blast cells isolated by FACS were negative for JAK2-V617F and displayed no 9pLOH (Figure 1B). Thus, the AML clone did not arise from a MPD progenitor heterozygous for JAK2-V617F that lost the mutated JAK2 allele during mitotic recombination. A similar conclusion was reached in another MPD patient who transformed to AML.23 Using the MPP1 expression assay to determine clonality by XCIP,24,25 we found that the granulocytes at MPD diagnosis were clonal (Figure 1A). At diagnosis of AML, peripheral blood granulocytes and leukemic blast cells purified from peripheral blood by FACS were clonal and expressed MPP1 from the same parental X chromosome as the granulocytes at MPD diagnosis (Figure 1B). This result is compatible with a common origin of the MPD and AML clone, but does not rule out that 2 clones arose independently, because the AML blasts could fortuitously have inactivated the same X chromosome as the MPD clone. In a second patient (NA-48) with initially JAK2-V617F–positive MPD, we found at the time of leukemic transformation JAK2-V617F to be absent in isolated blast cells, but present in unfractionated bone marrow cells with an allelic ratio of 51%T (Table 1; Figure S2). Del(11q) was found in 20 of 20 metaphases by cytogenetic analysis and in 99 of 100 cells by interphase fluorescence in situ hybridization (FISH). These data suggest that the JAK2-V617F–negative blasts and the JAK2-V617F–positive bone marrow cells carry the same deletion, implying that they share a common clonal origin. Interestingly, the same region on chromosome 11 was previously identified in a genome-wide screening for LOH.26 View larger version (24K): [in this window] [in a new window]   Figure 1. Analysis of clonal markers in patient NA-02. (A) Bone marrow samples at MPD diagnosis. The presence of the JAK2-V617F mutation was determined by AS-PCR using DNA from purified cells: CD15+, myeloid cells isolated by FACS; CD3+, T cells isolated by FACS. %T indicates the allelic ratio between the mutant and wild-type JAK2 allele. 9pLOH was determined with the microsatellite markers D9S1810 and D9S288 using DNA from purified cells as for JAK2. XCIP was determined by AS-PCR for a G/T polymorphism in the MPP1 mRNA. The relative expression of the 2 MPP1 alleles was determined by comparing the G and T peak intensities obtained by the allele-specific reverse transcription-PCR assay. (B) Peripheral blood samples at AML transformation. GRA, Granulocytes isolated by Ficoll density centrifugation; CD34+, leukemic blasts isolated by FACS; CD3+, T cells isolated by FACS. The assays were performed as in (A).   In summary, the unexpected finding of JAK2-V617F–negative leukemia in patients with previously JAK2-V617F–positive MPD could be explained by 2 models: first, MPD and AML represent 2 independent clones that arose de novo from different progenitor or stem cells, or second, MPD and AML are 2 subclones derived from a common ancestor. Our data on patient NA-02 are compatible with both models, whereas the results from patient NA-48 favor a common clonal origin of MPD and AML and suggest that an additional clonal event may precede the acquisition of JAK2-V617F in the pathogenesis of MPD.    Authorship Top Abstract Introduction Materials and methods Results and discussion Authorship References   Contribution: A. Theocharides performed research, analyzed data, and wrote the paper; M.B. performed research and analyzed data; F.G., R.G., and E.L. provided essential reagents and analyzed data; S.-S.T. performed research; P.T. performed cytogenetics and FISH studies; A. Tichelli analyzed data; S.H. designed and performed research and analyzed data; and R.C.S. designed research, analyzed data, and wrote the paper. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Radek C. Skoda, Department of Research, Experimental Hematology, University Hospital Basel, Hebelstrasse 20, 4031 Basel, Switzerland; e-mail: radek.skoda{at}unibas.ch.    Acknowledgments   We thank Verena Jäggin (Basel, Switzerland) for FACS sorting; Danielle Pineau (Nantes, France) for excellent technical assistance; Francine Mugneret (Dijon, France) for cytogenetic and FISH analyses; Céline Schaeffer (Dijon) for collecting patients' data; Jean-Luc Harousseau (Nantes) for allowing access to the patients' archived files; Denis Caillot (Dijon) and Bruno Salles (Châlon-sur-Saône, France) for providing samples and patient data; and Alois Gratwohl (Basel), Jürg Schwaller (Basel), Ralph Tiedt (Basel), and Robert Kralovics (Vienna, Austria) for comments on the manuscript. A. Theocharides was a fellow of the Postgraduate Course in Experimental Biology and Medicine funded by the Freiwillige Akademische Gesellschaft Basel and the Novartis Foundation. This work was supported by grants 310000-108006/1 from the Swiss National Science Foundation and the Swiss Cancer League (OCS-01742-08-2005) (R.C.S.) and from the Program Hospitalier de Recherche Clinique of the Région Bourgogne (F.G.), and from the Grand Ouest (S.H.) and Aquitaine-Charente (E.L.) Committees of the Ligue Nationale contre le Cancer.    Footnotes   Submitted December 8, 2006; accepted February 24, 2007. Prepublished online as Blood First Edition Paper, March 15, 2007 DOI: 10.1182/blood-2006-12-062125 The online version of this manuscript contains a data supplement. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results and discussion Authorship References   James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434:1144–1148.[CrossRef][Medline] [Order article via Infotrieve] Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054–1061.[Medline] [Order article via Infotrieve] Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7:387–397.[CrossRef][Medline] [Order article via Infotrieve] Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferativedisorders. N Engl J Med 2005; 352:1779–1790.[Abstract/Free Full Text] Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19:1847–1849.[CrossRef][Medline] [Order article via Infotrieve] Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108:1865–1867.[Abstract/Free Full Text] Jaffe ES, Harris NL, Stein H. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon IARC Press2001. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616–622.[Abstract/Free Full Text] Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M. Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation—a brief review of recent literature. Acta Haematol 1994; 91:84–88.[Medline] [Order article via Infotrieve] Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106:3377–3379.[Abstract/Free Full Text] Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207–1209.[Abstract/Free Full Text] Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106:3370–3373.[Abstract/Free Full Text] Scott LM, Campbell PJ, Baxter EJ, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106:2920–2921.[Free Full Text] Frohling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood 2006; 107:1242–1243.[Free Full Text] Lee JW, Kim YG, Soung YH, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006; 25:1434–1436.[CrossRef][Medline] [Order article via Infotrieve] Rossi D, Deambrogi C, Capello D, et al. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2006; 135:267–268.[CrossRef][Medline] [Order article via Infotrieve] Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131:208–213.[CrossRef][Medline] [Order article via Infotrieve] Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292–2302.[Abstract/Free Full Text] Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 1999; 36:9–13.[Medline] [Order article via Infotrieve] Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol 2001; 38:21–24.[Medline] [Order article via Infotrieve] Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 2006; 108:1781–1782.[Free Full Text] Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 2006; 108:1377–1380.[Abstract/Free Full Text] Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006; 108:3548–3555.[Abstract/Free Full Text] Luhovy M, Liu Y, Belickova M, Prchal JF, Prchal JT. A novel clonality assay based on transcriptional polymorphism of X chromosome gene p55. Biol Blood Marrow Transplant 1995; 1:81–87.[Medline] [Order article via Infotrieve] Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood 2003; 101:3294–3301.[Abstract/Free Full Text] Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30:229–236.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. J. Aichberger, A. G. Fleischman, and M. W. Deininger Same mutation, different allele Blood, October 1, 2009; 114(14): 2853 - 2854. [Full Text] [PDF] J. R. Lambert, T. Everington, D. C. Linch, and R. E. Gale In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm Blood, October 1, 2009; 114(14): 3018 - 3023. [Abstract] [Full Text] [PDF] H. Haeno, R. L. Levine, D. G. Gilliland, and F. Michor A progenitor cell origin of myeloid malignancies PNAS, September 29, 2009; 106(39): 16616 - 16621. [Abstract] [Full Text] [PDF] C. Saint-Martin, G. Leroy, F. Delhommeau, G. Panelatti, S. Dupont, C. James, I. Plo, D. Bordessoule, C. Chomienne, A. Delannoy, et al. Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms Blood, August 20, 2009; 114(8): 1628 - 1632. [Abstract] [Full Text] [PDF] F. H. Grand, C. E. Hidalgo-Curtis, T. Ernst, K. Zoi, C. Zoi, C. McGuire, S. Kreil, A. Jones, J. Score, G. Metzgeroth, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood, June 11, 2009; 113(24): 6182 - 6192. [Abstract] [Full Text] [PDF] R. L. Levine and M. Carroll A Common Genetic Mechanism in Malignant Bone Marrow Diseases N. Engl. J. Med., May 28, 2009; 360(22): 2355 - 2357. [Full Text] [PDF] A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] A. Theocharides, J. R. Passweg, M. Medinger, R. Looser, S. Li, H. Hao-Shen, A. S. Buser, A. Gratwohl, A. Tichelli, and R. C. Skoda The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders Haematologica, December 1, 2008; 93(12): 1890 - 1893. [Abstract] [Full Text] [PDF] F. Girodon, C. Schaeffer, C. Cleyrat, M. Mounier, I. Lafont, F. D. Santos, A. Vidal, M. Maynadie, and S. Hermouet Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy Haematologica, November 1, 2008; 93(11): 1723 - 1727. [Abstract] [Full Text] [PDF] F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, S. Boggi, C. Astori, P. Bernasconi, M. Varettoni, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients Haematologica, November 1, 2008; 93(11): 1645 - 1651. [Abstract] [Full Text] [PDF] R. L. Levine and D. G. Gilliland Myeloproliferative disorders Blood, September 15, 2008; 112(6): 2190 - 2198. [Abstract] [Full Text] [PDF] C. S. Tam, R. M. Nussenzveig, U. Popat, C. E. Bueso-Ramos, D. A. Thomas, J. A. Cortes, R. E. Champlin, S. E. Ciurea, T. Manshouri, S. M. Pierce, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms Blood, September 1, 2008; 112(5): 1628 - 1637. [Abstract] [Full Text] [PDF] J. P. Maciejewski and G. J. Mufti Whole genome scanning as a cytogenetic tool in hematologic malignancies Blood, August 15, 2008; 112(4): 965 - 974. [Abstract] [Full Text] [PDF] C. James The JAK2V617F Mutation in Polycythemia Vera and Other Myeloproliferative Disorders: One Mutation for Three Diseases? Hematology, January 1, 2008; 2008(1): 69 - 75. [Abstract] [Full Text] [PDF] R. L. Levine and M. Heaney New Advances in the Pathogenesis and Therapy of Essential Thrombocythemia Hematology, January 1, 2008; 2008(1): 76 - 82. [Abstract] [Full Text] [PDF] A. Rambaldi, T. Barbui, and G. Barosi From Palliation to Epigenetic Therapy in Myelofibrosis Hematology, January 1, 2008; 2008(1): 83 - 91. [Abstract] [Full Text] [PDF] E. Antonioli, P. Guglielmelli, G. Poli, V. Santini, A. Bosi, and A. M. Vannucchi Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance Blood, December 15, 2007; 110(13): 4620 - 4621. [Full Text] [PDF] G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, M. Massa, V. Rosti, R. Campanelli, L. Villani, et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis Blood, December 1, 2007; 110(12): 4030 - 4036. [Abstract] [Full Text] [PDF] R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF] R. Hoffman and D. Rondelli Biology and Treatment of Primary Myelofibrosis Hematology, January 1, 2007; 2007(1): 346 - 354. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Supplemental Table and Figures All Versions of this Article: blood-2006-12-062125v1 110/1/375    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Theocharides, A. Articles by Skoda, R. C. Search for Related Content PubMed PubMed Citation Articles by Theocharides, A. Articles by Skoda, R. C. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Brief Reports Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020